Kuros Biosciences reports results for the full year 2018

Schlieren (Zurich), Switzerland, April 12, 2019 – Kuros Biosciences successfully delivered on its targets in 2018, realizing first sales of MagnetOs and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds of CHF 16.1 million from a capital increase to advance...

read more

Molecular Partners to present pre-clinical data on its FAP x CD40 multi-DARPin® molecule and on DARPin® drug conjugates (DDCs) at the AACR 2019

Zurich-Schlieren, Switzerland, March 29, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that the company will present new pre-clinical data highlighting the company’s immuno-oncology and DARPin® directed drug delivery (DDC) platforms at the Annual Meeting 2019...

read more